NCT03980899 (EGERIPP 2) is a clinical trial in Proton Pump Inhibitor, sponsored by Fondation Hôpital Saint-Joseph.

Who is sponsoring NCT03980899?

NCT03980899 is sponsored by Fondation Hôpital Saint-Joseph.

What condition does NCT03980899 study?

NCT03980899 studies Proton Pump Inhibitor.

Is NCT03980899 still recruiting?

NCT03980899 is currently completed. Last updated 27 April 2023.

Last reviewed 2023-04-27 · How we verify

NCT03980899: EGERIPP 2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Long-term Tolerance of Proton Pump Inhibitor (PPI) Discontinuation in Geriatric Patients Treated With Long-term Therapy Without a Recognized Indication

Completed Last updated 27 April 2023

What this trial tests

trial in Proton Pump Inhibitor in 42 participants. Completed in 26 April 2023.

Timeline

4 July 2019

Primary endpoint
3 November 2020

26 April 2023

Quick facts

Lead sponsor	Fondation Hôpital Saint-Joseph
Status	Completed
Study type	OBSERVATIONAL
Enrollment	42
Start date	4 July 2019
Primary completion	3 November 2020
Estimated completion	26 April 2023
Sites	1 location across France

Conditions studied

Proton Pump Inhibitor — all drugs for Proton Pump Inhibitor →

Sponsor

Fondation Hôpital Saint-Joseph — full company profile →

Who can join

65 and older, any sex, with Proton Pump Inhibitor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Proton pump inhibitors (PPIs) are widely prescribed in France as anti-ulcer drugs. The indications currently approved in France, with variations according to molecules, are as follows: eradication of Helicobacter pylori, active peptic ulcer disease, maintenance treatment of duodenal ulcer disease, treatment of gastroduodenal lesions induced by non-steroidal anti-inflammatory drugs (NSAIDs), prevention of NSAID-induced gastro-duodenal lesions in at-risk subjects, symptomatic treatment of gastroesophageal reflux disease (GERD), esophagitis by GERD, maintenance treatment of esophagitis by GERD and Zollinger-Ellison syndrome. Several misuse situations had been identified by the High Authority of Health (HAS) in its reassessment in 2009. Although these molecules are very well tolerated in the short term, studies show the occurrence of long-term adverse effects such as an increase in the number of lung infections, Clostridium difficile infections and an increased risk of fractures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Proton Pump Inhibitor

Currently open trials in the same condition.

NCT07165444 — Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatme · NA · recruiting

Other Fondation Hôpital Saint-Joseph trials

Trials by the same sponsor.

NCT07512960 — Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia After Distal Revascularization · Phase 3 · not yet recruiting
NCT07512908 — Study of Factors Influencing the Dynamics of Colonisation and Decolonisation of the Digestive Tract by Clostridioides Di · NA · not yet recruiting
NCT07512830 — Evaluation of the Benefits of Hypnosis During Transoesophageal Echocardiography · NA · recruiting
NCT07348081 — Real World Evidence to Assess the Value of a Digital Care Coordination and Monitoring Program for Supporting Caregivers · NA · recruiting
NCT07086612 — Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) and Transverse Orthodontic Deficiency in Children · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03980899 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondation Hôpital Saint-Joseph
Last refreshed: 27 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03980899.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing